Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia.
A 38-year-old man diagnosed with pure red blood cell aplasia was undergoing treatment with cyclosporine 200 mg/day. On day 41, the cyclosporine dose was increased to 250 mg/day. On day 45, the patient was hospitalized with fever, and ciprofloxacin 200 mg IV tid was begun. The level of cyclosporine was 297 ng/mL, which obliged us to reduce cyclosporine to 200 mg/day. On day 59, ciprofloxacin was discontinued. On day 80, the patient was hospitalized with fever, and levofloxacin 500 mg/d IV was begun. The patient was continued on cyclosporine 250 mg/day. On day 90, levofloxacin was discontinued. The cyclosporine dose-to-blood level ratio was maintained constant in subsequent controls. In this patient, the substantial and sustained increase in cyclosporine blood levels after ciprofloxacin was added to the patient's therapy and the decrease in cyclosporine blood levels after the withdrawal of ciprofloxacin suggest a potential interaction. Levofloxacin therapy could be a therapeutic alternative, although pharmacokinetic/pharmacodynamic studies should be conducted.
Borrás-Blasco
Joaquín
J
Pharmacy Service, Hospital General Universitario de Elche, Elche, Spain.
Conesa-García
Venancio
V
Navarro-Ruiz
Andrés
A
Marín-Jiménez
Francisca
F
González-Delgado
Mercedes
M
Gomez-Corrons
Amparo
A
D000328:Adult; D002939:Ciprofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D016572:Cyclosporine / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy*
D002939:Ciprofloxacin; D064704:Levofloxacin; D016572:Cyclosporine; D015242:Ofloxacin